TrialNeuro-oncology2025

Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma.

William G Breen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.